1. Home
  2. PHIO

PHIO

Phio Pharmaceuticals Corp.

Logo Phio Pharmaceuticals Corp.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.

Founded: N/A Country:
United States
United States
Employees: 9 City: MARLBOROUGH
Market Cap: 2.9M IPO Year: N/A
Target Price: $4.00 AVG Volume (30 days): 321.4K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -5.20 EPS Growth: N/A
52 Week Low/High: $0.50 - $12.27 Next Earning Date: 05-09-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: